SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Hecla Mining Company approved a first amendment to extend its Amended and Restated Stock Plan for Nonemployee Directors through May 15, 2036, with no other plan provisions modified…
Granite Ridge Resources filed an amended and restated 2022 omnibus incentive plan to provide equity compensation opportunities to directors, officers, employees, consultants and ad…
Shore Bancshares Inc. filed its 2026 Code of Ethics and Business Conduct establishing ethical guidelines for all employees and directors. The policy emphasizes integrity, accountab…
iPower Inc. filed a Certificate of Amendment to its Articles of Incorporation with Nevada on May 20, 2026, modifying the first sentence of Article FOURTH concerning capital stock. …
Sadot Group Inc. submitted an amended certificate of incorporation as part of its SEC 8-K filing. The filing suggests potential corporate structure changes that may affect sharehol…
Anavex Life Sciences received a delinquency notification from Nasdaq on May 20, 2026, due to failure to timely file its Form 10-Q for Q2 2026, and has until July 20, 2026 to submit…
Assembly Biosciences announced expansion of its oral NTCP inhibitor ABI-6250 into primary biliary cholangitis and primary sclerosing cholangitis, with a Phase 2 study anticipated t…
Momentus amended its 2021 Equity Incentive Plan to increase Class A common stock reserves by 500,000 shares and raise the annual evergreen provision from 3.0% to 5.0%, pending stoc…
XOMA Royalty Corporation amended its bylaws to opt out of Nevada acquiring company statutes and designate Nevada courts as the exclusive forum for internal disputes, while federal …
All In FutureTech Alliance received a Nasdaq delisting notice on May 19, 2026 for non-compliance with timely filing requirements, but completed and filed its 2025 Annual Report on …
The Phase 2b LUMA study of BIIB122 failed to meet primary and secondary endpoints in early-stage Parkinson's disease, prompting discontinuation in idiopathic PD while continuing a …
Zentalis Pharmaceuticals presented Phase 1b MUIR trial results showing 39% overall response rate and 7.3-month median PFS for azenosertib combined with paclitaxel in platinum-resis…
Black Diamond Therapeutics announced positive Phase 2 results for silevertinib showing 15.2 months median PFS and 86% CNS ORR in frontline NSCLC patients with EGFR non-classical mu…
GSR V's May 15, 2026 balance sheet reveals substantial doubt about the company's ability to continue as a going concern due to limited cash and significant business combination pur…
GCI Liberty submitted an exhibit filing with the Nevada Secretary of State regarding corporate governance documentation. The filing appears to be a routine administrative matter wi…
Zelenectide pevedotin combined with pembrolizumab demonstrated response rates comparable to standard of care in metastatic urothelial cancer with approximately four-fold lower skin…
Olema Pharmaceuticals announced encouraging initial clinical data from Phase 1 testing of OP-3136, a KAT6 inhibitor, showing no dose-limiting toxicities and tumor shrinkage in two-…
Bicara's ficerafusp alfa plus pembrolizumab demonstrated approximately doubled overall survival compared to standard of care in first-line recurrent/metastatic HPV-negative head an…
Fulgent announced interim data from its Phase 2 study of FID-007 combined with cetuximab for recurrent/metastatic head and neck cancer, showing 60% objective response rate and favo…
Choice Hotels International filed a third amendment to its restated certificate of incorporation modifying Article 7 to establish board composition flexibility between 5 and 15 dir…